Open AccessManagement of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis
Author(s) -
J. Stuart Elborn,
P.A. Flume,
Donald R Van Devanter,
Claudio Procaccianti
Publication year - 2021
Publication title -
future microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.797
H-Index - 82
eISSN - 1746-0921
pISSN - 1746-0913
DOI - 10.2217/fmb-2021-0150
Subject(s) - cystic fibrosis , pseudomonas aeruginosa , levofloxacin , exacerbation , medicine , antimicrobial , chronic infection , copd , intensive care medicine , microbiology and biotechnology , immunology , antibiotics , biology , bacteria , immune system , genetics
People with cystic fibrosis (CF) are highly susceptible to bacterial infections of the airways. By adulthood, chronic Pseudomonas aeruginosa ( Pa) is the most prevalent infective organism and is difficult to eradicate owing to its adaptation to the CF lung microenvironment. Long-term suppressive treatment with inhaled antimicrobials is the standard care for reducing exacerbation frequency, improving quality of life and increasing measures of lung function. Levofloxacin (a fluoroquinolone antimicrobial) has been approved as an inhaled solution in Europe and Canada, for the treatment of adults with CF with chronic P. aeruginosa pulmonary infections. Here, we review the clinical principles relating to the use of inhaled antimicrobials and inhaled levofloxacin for the management of P. aeruginosa infections in patients with CF.